Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease
Authors: Mei Qiu
Journal: Annals of Internal Medicine (2022)

LettersJanuary 2022Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular DiseaseMei Qiu, MSMei Qiu, MSDepartment of General Medicine, Shenzhen Longhua District Central Hospital, Shenzhen, ChinaSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L21-0706 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:One of the main conclusions that Patorno and colleagues (1) draw is that there were no large differences between SGLT2 inhibitors and GLP-1 RAs in the risk for MI or stroke among patients with T2D with and without CVD. I believe that this conclusion is inconsistent with the findings revealed in Figure 2 of their article (1).As shown in Figure 2, compared with GLP-1 RAs, SGLT2 inhibitors were significantly associated with a reduced risk for primary cardiovascular outcomes (defined as a composite of hospitalization for either MI or stroke) in patients with T2D with CVD (hazard ...References1. Patorno E, Htoo PT, Glynn RJ, et al. Sodium–glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists and the risk for cardiovascular outcomes in routine care patients with diabetes across categories of cardiovascular disease. Ann Intern Med. 2021;174:1528-41. [PMID: 34570599] doi:10.7326/M21-0893 LinkGoogle Scholar2. Patorno E, Pawar A, Bessette LG, et al. Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists in older adults. Diabetes Care. 2021;44:826-35. [PMID: 33495295] doi:10.2337/dc20-1464 CrossrefMedlineGoogle Scholar3. Lugner M, Sattar N, Miftaraj M, et al. Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study. Cardiovasc Diabetol. 2021;20:67. [PMID: 33752680] doi:10.1186/s12933-021-01258-x CrossrefMedlineGoogle Scholar4. Longato E, Di Camillo, Sparacino G, et al. Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life. BMJ Open Diabetes Res Care. 2020;8. [PMID: 32591373] doi:10.1136/bmjdrc-2020-001451 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Department of General Medicine, Shenzhen Longhua District Central Hospital, Shenzhen, ChinaDisclosures: The author has reported no disclosures of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L21-0706. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoSodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease Elisabetta Patorno , Phyo T. Htoo , Robert J. Glynn , Sebastian Schneeweiss , Deborah J. Wexler , Ajinkya Pawar , Lily G. Bessette , Kristyn Chin , Brendan M. Everett , and Seoyoung C. Kim Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease Lurit Bepo , Anil N. Makam , and Oanh Kieu Nguyen Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease Elisabetta Patorno , Phyo T. Htoo , Brendan M. Everett , and Seoyoung C. Kim Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease Elisabetta Patorno , Phyo T. Htoo , Robert J. Glynn , Sebastian Schneeweiss , Deborah J. Wexler , Ajinkya Pawar , Lily G. Bessette , Kristyn Chin , Brendan M. Everett , and Seoyoung C. Kim Metrics January 2022Volume 175, Issue 1Page: W3-W4KeywordsCardiovascular diseasesCohort studiesDrugsHeart failureHemorrhagic strokeHospital medicineIschemic strokeMortalityMyocardial infarctionPopulation statistics ePublished: 18 January 2022 Issue Published: January 2022 Copyright & PermissionsCopyright © 2022 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...